{"id":"https://openalex.org/W2779549060","doi":null,"title":"Nivolumab (Opdivo\u00ae) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)","display_name":"Nivolumab (Opdivo\u00ae) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)","publication_year":2017,"publication_date":"2017-12-01","ids":{"openalex":"https://openalex.org/W2779549060","mag":"2779549060"},"language":"en","primary_location":{"id":"mag:2779549060","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/1144/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013647089","display_name":"N. Gr\u00f6ssmann","orcid":"https://orcid.org/0000-0003-4395-4667","observed_orcids":["https://orcid.org/0000-0003-4395-4667"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"N. Gr\u00f6ssmann","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4395-4667","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5013647089"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.26193666,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9549999833106995},{"id":"https://openalex.org/keywords/mismatch-repair-deficiency","display_name":"mismatch repair deficiency","score":0.968999981880188},{"id":"https://openalex.org/keywords/microsatellite-instability-high","display_name":"microsatellite instability-high","score":0.9760000109672546},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6639999747276306},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.9300000071525574},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6600000262260437},{"id":"https://openalex.org/keywords/fda-accelerated-approval","display_name":"accelerated FDA approval","score":0.6269999742507935},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6309999823570251},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8450000286102295},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6470000147819519},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.5040000081062317}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9522396326065063},{"id":"https://openalex.org/C2779767149","wikidata":"https://www.wikidata.org/wiki/Q488212","display_name":"Microsatellite instability","level":5,"score":0.8225122690200806},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.796368420124054},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7650371789932251},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.7290927767753601},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.7238671779632568},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6561577320098877},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5838594436645508},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5167733430862427},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.46071964502334595},{"id":"https://openalex.org/C60748783","wikidata":"https://www.wikidata.org/wiki/Q2984243","display_name":"DNA mismatch repair","level":4,"score":0.4100069999694824},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3371255397796631},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07995480298995972},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C61320498","wikidata":"https://www.wikidata.org/wiki/Q265193","display_name":"Microsatellite","level":4,"score":0.0},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2779549060","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/1144/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2739132742","https://openalex.org/W2601242481","https://openalex.org/W2794744201","https://openalex.org/W4392393143","https://openalex.org/W3005488763","https://openalex.org/W4233960244","https://openalex.org/W2794590332","https://openalex.org/W2784868445","https://openalex.org/W3206775306","https://openalex.org/W2793069904"],"abstract_inverted_index":{"Nivolumab":[0],"is":[1,23,97,108,119,143],"a":[2,90,116,219,225],"human":[3],"immunoglobulin":[4],"G4":[5],"(IgG4)":[6],"monoclonal":[7],"antibody,":[8],"that":[9,65,84,118,142],"blocks":[10],"binding":[11],"of":[12,30,63,139,157,170,178,213,231,251,269,284,287,290,309,317,324,351],"PD-1":[13],"(programmed":[14],"cell":[15],"death-1)":[16],"to":[17,151,305,377,395],"PD-L1":[18,22],"and":[19,37,51,69,76,93,129,155,222,300],"PD-L2.":[20],"Since":[21],"upregulated":[24],"in":[25,102,133,145,160,204,282,315,346,362],"some":[26],"tumours,":[27],"the":[28,48,61,111,130,140,146,153,168,179,229,236,249,267,270,306,322,342,349,354,366,379],"blockade":[29],"these":[31,42],"interactions":[32],"can":[33],"retrieve":[34],"T-cell":[35],"activity":[36,154],"cell-mediated":[38],"immune":[39],"response":[40,186,221],"against":[41],"tumour":[43],"cells.":[44],"In":[45,254,320],"July":[46],"2017,":[47],"US":[49],"Food":[50],"Drug":[52],"Administration":[53],"(FDA)":[54],"granted":[55],"accelerated":[56],"approval":[57,107],"for":[58,60,100,353,368,383],"nivolumab":[59,96,127,132,158,325],"treatment":[62,88,308,323,381],"patients":[64,162,182,207,217,291,385,398],"are":[66],"12":[67],"years":[68],"older":[70],"with":[71,89,135,163,333,348,386],"DNA":[72],"mismatch":[73],"repair-deficient":[74],"(dMMR)":[75],"microsatellite":[77],"instability-high":[78],"(MSI-H)":[79],"metastatic":[80,164],"colorectal":[81],"cancer":[82],"(CRC),":[83],"have":[85,280],"progressed":[86],"following":[87],"fluoropyrimidine,":[91],"oxaliplatin,":[92],"irinotecan.":[94],"Currently,":[95],"not":[98,246,263],"approved":[99],"CRC":[101,361,384],"Europe.":[103],"The":[105,137],"FDA":[106],"based":[109],"on":[110],"CheckMate":[112],"142":[113],"study":[114,141,307],"-":[115],"trial":[117],"separated":[120],"into":[121],"two":[122],"parts,":[123],"one":[124],"part":[125,138],"investigating":[126],"monotherapy":[128,159],"other":[131],"combination":[134,347],"ipilimumab.":[136],"examined":[144],"present":[147],"report":[148],"was":[149,241,245],"conducted":[150],"assess":[152],"safety":[156,274,336],"74":[161,180],"dMMR/MSI-H":[165],"CRC.":[166],"At":[167],"time":[169,250,268],"data":[171,252,345],"cut-off":[172],"(3":[173],"January":[174],"2017)":[175],"23":[176],"(31.1%)":[177],"included":[181],"demonstrated":[183,330],"an":[184,334],"objective":[185],"(OR)":[187],"\u2013":[188],"all":[189],"responses":[190,332],"were":[191],"partial":[192,226,331],"(investigator-assessed).":[193],"An":[194],"OR":[195],"assessed":[196],"by":[197,360],"blinded":[198],"independent":[199],"central":[200],"review":[201],"(BICR)":[202],"occurred":[203,281,314],"24":[205],"(32%)":[206],"(dMMR/MSI-H":[208],"per":[209],"local":[210],"assessment),":[211],"out":[212,286],"those":[214,288,397],"2":[215],"(3%)":[216],"had":[218,262,292],"complete":[220],"22":[223],"(30%)":[224],"one.":[227],"After":[228],"occurence":[230],"36":[232],"investigator-assessed":[233],"progression":[234],"events,":[235],"median":[237,256],"progression-free":[238],"survival":[239,258],"(PFS)":[240],"14.3":[242],"months,":[243],"but":[244],"mature":[247],"at":[248,266,338],"cut-off.":[253],"addition,":[255],"overall":[257],"(OS)":[259],"(23":[260],"deaths)":[261],"been":[264],"reached,":[265],"interim":[271],"analysis.":[272],"Regarding":[273],"outcomes,":[275],"drug-related":[276],"adverse":[277],"events":[278],"(AEs)":[279],"70%":[283],"patients,":[285],"20%":[289],"grade":[293,310],"\u22653":[294],"AEs":[295,303],"(most":[296],"frequent:":[297],"increased":[298],"lipase":[299],"amylase).":[301],"Serious":[302],"related":[304],"3":[311],"or":[312],"higher":[313],"12%":[316],"patients.":[318],"conclusion,":[321],"offers":[326],"durable":[327],"responses,":[328],"31.1%":[329],"acceptable":[335],"profile":[337],"high":[339],"costs.":[340],"However,":[341],"immature":[343],"OS":[344],"lack":[350],"evidence":[352],"actual":[355],"patient":[356],"population":[357],"affected":[358],"most":[359,401],"clinical":[363],"practice":[364],"highlight":[365],"requirement":[367],"long-term":[369],"data.":[370],"Moreover,":[371],"head-to-head":[372],"comparisons":[373],"will":[374,392],"be":[375,393],"necessary":[376],"identify":[378],"best":[380],"option":[382],"dMMR/MSI-H.":[387],"Ultimately,":[388],"trustworthy":[389],"biomarker":[390],"testing":[391],"needed":[394],"select":[396],"who":[399],"benefit":[400],"from":[402],"nivolumab.":[403]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2018-01-05T00:00:00"}